| Literature DB >> 33187053 |
Vladimir I Chernov1, Evgeniy L Choynzonov1, Denis E Kulbakin1, Ekaterina N Menkova1, Elena V Obkhodskaya2, Artem V Obkhodskiy2,3, Aleksandr S Popov2,3, Evgeniy O Rodionov1, Victor I Sachkov2, Anna S Sachkova3.
Abstract
Novel non-invasive methods for the diagnosis of malignancies should be effective for early diagnosis, reproducible, inexpensive, and independent from the human factor. Our aim was to establish the applicability of the non-invasive method, based on the analysis of air exhaled by patients who are at different stages of oropharyngeal, larynx and lung cancer. The diagnostic device includes semiconductor sensors capable of measuring the concentrations of gas components in exhaled air, with the high sensitivity of 1 ppm. The neural network uses signals from these sensors to perform classification and identify cancer patients. Prior to the diagnostic procedure of the non-invasive method, we clarified the extent and stage of the tumor according to current international standards and recommendations for the diagnosis of malignancies. The statistical dataset for neural network training and method validation included samples from 121 patients with the most common tumor localizations (lungs, oropharyngeal region and larynx). The largest number of cases (21 patients) were lung cancer, while the number of patients with oropharyngeal or laryngeal cancer varied from 1 to 9, depending on tumor localization (oropharyngeal, tongue, oral cavity, larynx and mucosa of the lower jaw). In the case of lung cancer, the parameters of the diagnostic device are determined as follows: sensitivity-95.24%, specificity-76.19%. For oropharyngeal cancer and laryngeal cancer, these parameters were 67.74% and 87.1%, respectively. This non-invasive method could lead to relevant medicinal findings and provide an opportunity for clinical utility and patient benefit upon early diagnosis of malignancies.Entities:
Keywords: cancer; exhaled air; malignancy; markers; neural network; non-invasive diagnosis; sensor-based gas analyzer
Year: 2020 PMID: 33187053 PMCID: PMC7696783 DOI: 10.3390/diagnostics10110934
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Characteristics of the study set of patients.
|
| % | |
|---|---|---|
| Number of patients with malignant pathology | 52 | 43.0 |
| Mean age | 60 | |
| Sex | ||
| Male | 43 | 82.7 |
| Female | 9 | 17.3 |
| TNM* staging | ||
| I | 8 | 15.4 |
| II | 23 | 44.2 |
| III | 15 | 28.8 |
| IV | 6 | 11.6 |
| Localization | ||
| Lungs | 21 | 40.4 |
| Larynx | 9 | 17.3 |
| Oral cavity | 5 | 9.6 |
| Oropharynx | 7 | 13.5 |
| Hypopharynx | 1 | 1.9 |
| Tongue | 6 | 11.6 |
| The mucous membrane of the alveolar process of the lower jaw | 3 | 5.7 |
| Tobacco consumption | ||
| Yes | 29 | 55.8 |
| No | 23 | 44.2 |
TNM* System—TNM Classification of Malignant Tumors.
Characteristics of the control set of patients.
|
| % | |
|---|---|---|
| Control group (with no data on malignant pathology) | 69 | 57.0 |
| Mean age | 50 | |
| Sex | ||
| Male | 14 | 20.3 |
| Female | 55 | 79.7 |
Figure 1Form of sensor signals (ADC—analog-to-digital converter).
Figure 2Scatter plot for all healthy patients, patients with laryngeal or oropharyngeal cancer, and patients with lung cancer.
Figure 3ROC (receiver operating characteristic) curve for all healthy patients, patients with lung cancer, and patients with laryngeal or oropharyngeal cancer (black curve—ROC curve, grey line—Reference line and grey x—experimental points).
Figure 4Scatter plot for healthy patients and lung cancer patients.
Figure 5ROC curve for healthy patients and lung cancer patients (black curve—ROC curve, grey line—Reference line and grey x—experimental points).
Figure 6Scatter plot for healthy patients and patients with laryngeal or oropharyngeal cancer.
Figure 7ROC curve for healthy patients and patients with laryngeal or oropharyngeal cancer (black curve—ROC curve, grey line—Reference line and grey x—experimental points).
Achieved parameters of the gas analysis system.
| N | Data Set Parameters | Accuracy | Sensitivity | Specificity |
|---|---|---|---|---|
| 1 | 69 healthy subjects and 31 subjects with laryngeal or oropharyngeal cancer + 21 subjects with lung cancer | 80.16% | 76.92% | 82.61% |
| 2 | 21 healthy subjects and 21 subjects with lung cancer | 85.71% | 95.24% | 76.19% |
| 3 | 31 healthy subjects and 31 laryngeal or oropharyngeal cancer | 77.41% | 67.74% | 87.1% |